Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Miller KD , Nogueira L , Mariotto AB et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 69(5), 363–385 (2019).
  MedlineGoogle Scholar
• 2. Balch CM , Gershenwald JE , Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199–6206 (2009).
  MedlineGoogle Scholar
• 3. Luke JJ , Flaherty KT , Ribas A , Long GV . Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14(8), 463–482 (2017).
  Medline CASGoogle Scholar
• 4. Robert C , Long GV , Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320–330 (2015).
  Medline CASGoogle Scholar
• 5. Postow MA , Chesney J , Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006–2017 (2015).
  MedlineGoogle Scholar
• 6. Larkin J , Chiarion-Sileni V , Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
  Medline CASGoogle Scholar
• 7. Long GV , Stroyakovskiy D , Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, Phase III randomised controlled trial. Lancet 386(9992), 444–451 (2015).
  Medline CASGoogle Scholar
• 8. Robert C , Karaszewska B , Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372(1), 30–39 (2015).
  Medline CASGoogle Scholar
• 9. Vinay DS , Ryan EP , Pawelec G et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35(Suppl.), S185–S198 (2015).
  MedlineGoogle Scholar
• 10. Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252–264 (2012).
  Medline CASGoogle Scholar
• 11. Coley W . The treatment of malignant tumors by repeated innoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 10, 487–511 (1893).
  Google Scholar
• 12. Miura JT , Zager JS . Intralesional therapy as a treatment for locoregionally metastatic melanoma. Expert Rev. Anticancer Ther. 18(4), 399–408 (2018). • Provides a comprehensive review of the different intralesional agents that have been investigated or are undergoing active investigation for advanced melanoma.
  Medline CASGoogle Scholar
• 13. Kohlhapp FJ , Kaufman HL . Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin. Cancer Res. 22(5), 1048–1054 (2016).
  Medline CASGoogle Scholar
• 14. Andtbacka RH , Kaufman HL , Collichio F et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33(25), 2780–2788 (2015). • First study to demonstrate the efficacy of intralesional immune-based agents for advanced melanoma at the Phase III level.
  Medline CASGoogle Scholar
• 15. Liao W , Lin JX , Leonard WJ . Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38(1), 13–25 (2013).
  Medline CASGoogle Scholar
• 16. Cantrell DA , Smith KA . The interleukin-2 T-cell system: a new cell growth model. Science 224(4655), 1312–1316 (1984).
  Medline CASGoogle Scholar
• 17. Atkins MB , Lotze MT , Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105–2116 (1999).
  Medline CASGoogle Scholar
• 18. Eklund JW , Kuzel TM . A review of recent findings involving interleukin-2-based cancer therapy. Curr. Opin. Oncol. 16(6), 542–546 (2004).
  Medline CASGoogle Scholar
• 19. Smith FO , Downey SG , Klapper JA et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14(17), 5610–5618 (2008).
  Medline CASGoogle Scholar
• 20. Baluna R , Sausville EA , Stone MJ , Stetler-Stevenson MA , Uhr JW , Vitetta ES . Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. Clin. Cancer Res. 2(10), 1705–1712 (1996).
  Medline CASGoogle Scholar
• 21. Weide B , Derhovanessian E , Pflugfelder A et al. High response rate after intratumoral treatment with interleukin-2: results from a Phase II study in 51 patients with metastasized melanoma. Cancer 116(17), 4139–4146 (2010). •• Phase II study demonstrating a complete response rate of 69% following intralesional IL-2 administration for metastatic melanoma.
  Medline CASGoogle Scholar
• 22. Radny P , Caroli UM , Bauer J et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br. J. Cancer 89(9), 1620–1626 (2003).
  Medline CASGoogle Scholar
• 23. Byers BA , Temple-Oberle CF , Hurdle V , Mckinnon JG . Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. J. Surg. Oncol. 110(6), 770–775 (2014).
  Medline CASGoogle Scholar
• 24. Ridolfi L , Ridolfi R , Ascari-Raccagni A et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J. Eur. Acad. Dermatol. Venereol. 15(3), 218–223 (2001).
  Medline CASGoogle Scholar
• 25. Danielli R , Patuzzo R , Di Giacomo AM et al. Intralesional administration of L19-IL-2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a Phase II study. Cancer Immunol. Immunother. 64(8), 999–1009 (2015). •• Phase II study that demonstrated high overall response rates following intralesional L19IL-2/L19TNF. Favorable results served as the foundation for the presented Neo-DREAM study.
  Medline CASGoogle Scholar
• 26. Deroose JP , Eggermont AM , Van Geel AN , De Wilt JH , Burger JW , Verhoef C . 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann. Surg. Oncol. 19(2), 627–635 (2012).
  MedlineGoogle Scholar
• 27. Bartsch HH , Pfizenmaier K , Schroeder M , Nagel GA . Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur. J. Cancer Clin. Oncol. 25(2), 287–291 (1989).
  Medline CASGoogle Scholar
• 28. Grunhagen DJ , De Wilt JH , Van Geel AN , Eggermont AM . Isolated limb perfusion for melanoma patients–a review of its indications and the role of tumour necrosis factor-alpha. Eur. J. Surg. Oncol. 32(4), 371–380 (2006).
  Medline CASGoogle Scholar
• 29. Reisfeld RA , Gillies SD . Recombinant antibody fusion proteins for cancer immunotherapy. Curr. Top. Microbiol. Immunol. 213(Pt 3), 27–53 (1996).
  Medline CASGoogle Scholar
• 30. Carnemolla B , Borsi L , Balza E et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99(5), 1659–1665 (2002).
  MedlineGoogle Scholar
• 31. Frey K , Fiechter M , Schwager K et al. Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp. Dermatol. 20(8), 685–688 (2011).
  Medline CASGoogle Scholar
• 32. Pretto F , Elia G , Castioni N , Neri D . Preclinical evaluation of IL-2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol. Immunother. 63(9), 901–910 (2014). •• Preclinical study to demonstrate the selective localizing properties of immunocytokines and its ability to eradicate cancer cells.
  Medline CASGoogle Scholar
• 33. Borsi L , Balza E , Carnemolla B et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102(13), 4384–4392 (2003).
  Medline CASGoogle Scholar
• 34. Balza E , Carnemolla B , Mortara L et al. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int. J. Cancer 127(1), 101–110 (2010).
  Medline CASGoogle Scholar
• 35. Schwager K , Hemmerle T , Aebischer D , Neri D . The immunocytokine L19-IL-2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J. Invest. Dermatol. 133(3), 751–758 (2013). •• Demonstrates the synergistic effects of combination L19IL-2 and L19TNF in preclinical models.
  Medline CASGoogle Scholar
• 36. Weide B , Eigentler TK , Pflugfelder A et al. Intralesional treatment of stage III metastatic melanoma patients with L19-IL-2 results in sustained clinical and systemic immunologic responses. Cancer Immunol. Res. 2(7), 668–678 (2014).
  Medline CASGoogle Scholar
• 37. Eggermont AMM , Robert C , Ribas A . The new era of adjuvant therapies for melanoma. Nat. Rev. Clin. Oncol. 15(9), 535–536 (2018).
  Medline CASGoogle Scholar
• 38. O'donnell JS , Hoefsmit EP , Smyth MJ , Blank CU , Teng MWL . The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-18-2641 (2019) (Epub ahead of print).
  MedlineGoogle Scholar
• 39. Helmink B , Wargo JA . Neoadjuvant therapy for melanoma: is it ready for prime time? Lancet Oncol. 20(7), 892–894 (2019).
  MedlineGoogle Scholar
• 40. Amaria RN , Prieto PA , Tetzlaff MT et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, Phase II trial. Lancet Oncol. 19(2), 181–193 (2018).
  Medline CASGoogle Scholar
• 41. Blank CU , Rozeman EA , Fanchi LF et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24(11), 1655–1661 (2018).
  Medline CASGoogle Scholar